LLY

1,024.63

-0.71%↓

JNJ

240.77

+0.94%↑

ABBV

221.51

-1.29%↓

NVS

159.95

+1.01%↑

MRK

118.67

+1.51%↑

LLY

1,024.63

-0.71%↓

JNJ

240.77

+0.94%↑

ABBV

221.51

-1.29%↓

NVS

159.95

+1.01%↑

MRK

118.67

+1.51%↑

LLY

1,024.63

-0.71%↓

JNJ

240.77

+0.94%↑

ABBV

221.51

-1.29%↓

NVS

159.95

+1.01%↑

MRK

118.67

+1.51%↑

LLY

1,024.63

-0.71%↓

JNJ

240.77

+0.94%↑

ABBV

221.51

-1.29%↓

NVS

159.95

+1.01%↑

MRK

118.67

+1.51%↑

LLY

1,024.63

-0.71%↓

JNJ

240.77

+0.94%↑

ABBV

221.51

-1.29%↓

NVS

159.95

+1.01%↑

MRK

118.67

+1.51%↑

Search

Charles River Laboratories International Inc

Fechado

SetorSaúde

181.27 -2.3

Visão Geral

Variação de preço das ações

24h

Atual

Mín

177.97

Máximo

183.32

Indicadores-chave

By Trading Economics

Rendimento

2.9M

56M

Vendas

-27M

1B

EPS

2.43

Margem de lucro

5.529

Funcionários

18,700

EBITDA

-23M

198M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+24.57% upside

Dividendos

By Dow Jones

Próximos Ganhos

18 de fev. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

337M

9.1B

Abertura anterior

183.57

Fecho anterior

181.27

Sentimento de Notícias

By Acuity

94%

6%

334 / 352 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

Charles River Laboratories International Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

10 de fev. de 2026, 23:26 UTC

Grandes Movimentos do Mercado

Moderna Stock Slips After FDA Refuses Flu Vaccine Review

10 de fev. de 2026, 22:31 UTC

Ganhos

Correction to America Movil 4Q Profit Article

10 de fev. de 2026, 22:22 UTC

Ganhos

America Movil 4Q Profit Jumps on Lower Financial Costs

10 de fev. de 2026, 23:51 UTC

Conversa de Mercado
Ganhos

Commonwealth Bank's Margin Management Gives It a Platform -- Market Talk

10 de fev. de 2026, 23:42 UTC

Conversa de Mercado

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

10 de fev. de 2026, 23:40 UTC

Conversa de Mercado
Ganhos

Commonwealth Bank Bear Says 1H Result Looks Strong -- Market Talk

10 de fev. de 2026, 23:21 UTC

Conversa de Mercado

Ford Says EV Shift Was Driven by Demand Changes -- Market Talk

10 de fev. de 2026, 23:21 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

10 de fev. de 2026, 22:17 UTC

Conversa de Mercado

Australia's One Nation Now Commands Working Class Vote -- Market Talk

10 de fev. de 2026, 22:15 UTC

Ganhos

Humana Earnings Will Shed More Light on Medicare Prospects -- Barrons.com

10 de fev. de 2026, 22:10 UTC

Ganhos

Intact Financial 4Q Book Value Per Share Was C$107.35 >IFC.T

10 de fev. de 2026, 22:10 UTC

Ganhos

Intact Financial Raises Qtr Dividend to C$1.47 >IFC.T

10 de fev. de 2026, 22:09 UTC

Ganhos

Intact Financial 4Q Combined Ratio Was 85.9% >IFC.T

10 de fev. de 2026, 22:09 UTC

Ganhos

Intact Financial 4Q Adj EPS C$5.50 >IFC.T

10 de fev. de 2026, 22:01 UTC

Ganhos

Intact Financial 4Q EPS C$5.24 >IFC.T

10 de fev. de 2026, 21:54 UTC

Ganhos

James Hardie Industries Sees FY26 Total Adjusted EBITDA $1.232B to $1.263B >JHX

10 de fev. de 2026, 21:53 UTC

Ganhos

Robinhood Stock Tumbles as Crypto-Related Revenue Falls Short of Expectations -- Barrons.com

10 de fev. de 2026, 21:51 UTC

Ganhos

James Hardie Industries Sees FY26 Free Cash Flow at Least $200M

10 de fev. de 2026, 21:51 UTC

Ganhos

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

10 de fev. de 2026, 21:51 UTC

Ganhos

James Hardie Industries: Focused on the Achievement of $125 M Target >JHX

10 de fev. de 2026, 21:51 UTC

Ganhos

James Hardie Industries: Integration and Cost Synergies Ahead of Schedule >JHX

10 de fev. de 2026, 21:51 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Evolution Net Debt A$362 Million at Dec. 31 Vs A$1.29 Billion Year Earlier

10 de fev. de 2026, 21:50 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Evolution: Gearing 6% at Dec. 31, From 23% a Year Earlier

10 de fev. de 2026, 21:50 UTC

Ganhos

James Hardie Industries 3Q EPS 12c >JHX

10 de fev. de 2026, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

10 de fev. de 2026, 21:50 UTC

Ganhos

James Hardie Industries 3Q Adj EPS 24c >JHX

10 de fev. de 2026, 21:49 UTC

Ganhos

James Hardie Industries 3Q Sales $1.24B >JHX

10 de fev. de 2026, 21:49 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Evolution 1H Operating Mine Cash Flow a Record A$1.73 Billion

10 de fev. de 2026, 21:48 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Evolution 1H Ebitda A$1.56 Billion, Up 59% On-Year

10 de fev. de 2026, 21:47 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Evolution 1H Revenue A$2.79 Billion, Up 37% On-Year

Comparação entre Pares

Variação de preço

Charles River Laboratories International Inc Previsão

Preço-alvo

By TipRanks

24.57% parte superior

Previsão para 12 meses

Média 231.33 USD  24.57%

Máximo 265 USD

Mínimo 190 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Charles River Laboratories International Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

11 ratings

9

Comprar

2

Manter

0

Vender

Pontuação Técnica

By Trading Central

117.16 / 144.77Suporte e Resistência

Curto Prazo

Strong Bullish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

334 / 352 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat